PharmTech Drug Digest 11.20
News|Articles|May 5, 2014

Pharmatek Launches New API Manufacturing Program

Pharmatek develops two new cGMP manufacturing suites for API-in-capsule productions.

Pharmatek, a contract development and manufacturing organization, has launched a new API-in-capsule manufacturing program. The program is designed to address manufacturing strategies that will lower development cost, shorten timelines, and increase capsule throughput for API-in-capsule productions.

As part of the program, Pharmatek has developed two new cGMP manufacturing suites designed specifically for API-in-capsule productions. The suites include humidity control and inert gas systems, which contribute to a stronger manufacturing process for API-in-capsule productions. In addition, Pharmatek has implemented operational systems to further address efficiencies, including new project teams, updated batch records, extended shift operations, redundant equipment and change parts, and on-demand inventory management.

Source: Pharmatek


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.